Evaluation of Memory and Forgetting in Patients With Epilepsy
NCT ID: NCT04924933
Last Updated: 2025-06-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
83 participants
INTERVENTIONAL
2022-01-26
2025-05-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of Interictal Electroencephalographic Abnormalities on the Stability of Attention in the Epilepsies
NCT03094793
Study on Neurocognitive Plasticity in Patients With Focal and Drug-resistant Epilepsy
NCT03543267
Multimodal Imaging in Pre-surgical Evaluation of Epilepsy
NCT01735032
Acute and Long Term Effects of VNS on Memory in Patients With Refractory Epilepsy
NCT05031208
Evaluation of the Risk of Cognitive Deficit After Surgery of Epilepsy by Dynamic Spectral Imaging (ISD) of the Cognitive Functions in Patients Explored in StereoElectroEncephaloGraphy (SEEG)
NCT03094312
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients (Epilepsy group)
Patients with drug-resistant focal epilepsy in whom an accelerated long-term forgetting is suspected (presence of a subjective memory complaint and absence of objective deficit in memory tests conducted in the frame of a routine comprehensive neuropsychological assessment)
Computerised associative memory task using abstract words and landscape photographs
Two test sessions using the computerised associative memory task will be performed by the two groups (patients and control subjects). The first session will consist of the encoding of 56 associations between a word and a photograph and the recall of half of them (28) 30 minutes later by the mean of a matching task and a recognition task. The second session consists of the recall of the other half of the associations (28) 72 hours after the encoding phase, using the same procedure (matching task and recognition task). Performance obtained by patients and by healthy volunteers will then be compared.
Healthy volunteers (control group)
Age-matched healthy volunteers
Computerised associative memory task using abstract words and landscape photographs
Two test sessions using the computerised associative memory task will be performed by the two groups (patients and control subjects). The first session will consist of the encoding of 56 associations between a word and a photograph and the recall of half of them (28) 30 minutes later by the mean of a matching task and a recognition task. The second session consists of the recall of the other half of the associations (28) 72 hours after the encoding phase, using the same procedure (matching task and recognition task). Performance obtained by patients and by healthy volunteers will then be compared.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Computerised associative memory task using abstract words and landscape photographs
Two test sessions using the computerised associative memory task will be performed by the two groups (patients and control subjects). The first session will consist of the encoding of 56 associations between a word and a photograph and the recall of half of them (28) 30 minutes later by the mean of a matching task and a recognition task. The second session consists of the recall of the other half of the associations (28) 72 hours after the encoding phase, using the same procedure (matching task and recognition task). Performance obtained by patients and by healthy volunteers will then be compared.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient who recently benefit from a comprehensive neuropsychological assessment (≤2 years)
* Patient presenting a subjective memory complaint consistent with an ALF
* Patient who obtained normal performance at memory tests during the comprehensive neuropsychological assessment
* Patient who gave its written informed consent to participate to the study
* Patient with corrected or non-corrected visual acuity allowing fluid reading on a computer screen
* Patient affiliated to the French health care system
* Adult (≥ 18 years old) without any neurological or psychiatric history
* Adult who gave its written informed consent to participate to the study
* Adult with corrected or non-corrected visual acuity allowing fluid reading on a computer screen
* Adult with normal scores on the Montreal Cognitive Assessment (MoCA) and the Matrix reasoning sub-test of the Fourth Edition Wechsler Adult Intelligence Scale (MoCA ≥ 27/30, Matrix reasoning \>5)
Exclusion Criteria
* Patient suffering from a major depressive syndrome (score \>15 on the French version of the Neurological Disorders Depression Inventory for Epilepsy - NDDIE)
* Patient who have undergone epilepsy surgery
* Patient who presented a seizure within the hour preceding the first test session
* Protected major
* Pregnant or breastfeeding woman
Control group
* Adult suffering from a depressive syndrome or a significative anxiety (score ≥ 8 in each dimension of the French version of the Hospital Anxiety and Depression Scale - HADS)
* Adult presenting a spontaneous subjective memory complaint
* Protected major
* Pregnant or breastfeeding woman
18 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospices Civils de Lyon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Victoria Guinet, PhD student
Role: PRINCIPAL_INVESTIGATOR
Service de Neurologie Fonctionnelle et d'Epileptologie
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospices Civils de Lyon Service de Neurologie Fonctionnelle et d'Epileptologie
Bron, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021-A01075-36
Identifier Type: OTHER
Identifier Source: secondary_id
69HCL21_0264
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.